1.
Bioorg Med Chem Lett
; 17(22): 6326-9, 2007 Nov 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17869514
RESUMO
Neutral 5-substituted 4-anilinoquinazolines addressed high in vivo clearance and phospholipidosis associated with previous basic compounds. A representative compound 8a inhibited tumor growth in a mouse xenograft model when co-administered with the cytochrome P450 inhibitor 1-aminobenzotriazole (ABT), and data are consistent with pharmacology primarily reflecting inhibition of erbB2 receptor tyrosine kinase.